Summer reads with unexpected lessons for biopharma leaders

From an inspiring rags-to-riches journey to a heroic rescue story at sea, here are a few books recommended by biopharma execs and what they can teach about leadership.

By Alexandra Pecci • May 19, 2026

Race intensifies to lead next wave of obesity drugs as trial results loom

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

By Kelly Bilodeau • May 18, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Sanofi’s vaccine bump; the new FDA commish

Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Sanofi’s vaccine bump ‘Sanofi’s vaccine sales are on the upswing this year, thanks to a boost from its newly acquired hepatitis ...

By PharmaVoice staff • May 15, 2026

Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech

The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.

By Meagan Parrish • May 15, 2026

FDA chief’s exit clouds already murky drug approvals

During Dr. Martin Makary’s tenure as commissioner, the FDA faced pushback over high-profile drug rejections for Replimune and UniQure.

By Kelly Bilodeau • May 14, 2026

Why the FDA’s push for real-time clinical trials could favor Big Pharma

The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.

By Alivia Kaylor • May 13, 2026

Cancer, immunology startups lead latest wave of stealth exits

A handful of recently debuted biotechs reveal where drug R&D is headed next.

By Alexandra Pecci • May 11, 2026

Biotech layoffs are easing, but is the worst over?

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

By Kelly Bilodeau • May 8, 2026

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.

By Kelly Bilodeau • May 7, 2026

Protein degraders gain speed as Arvinas scores landmark approval

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

By Kelly Bilodeau • May 4, 2026

Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?

Results show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.

By Kelly Bilodeau • April 29, 2026

Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.

By Alexandra Pecci • April 28, 2026

FDA’s need for speed could strain small biotechs. Here’s how they can keep up.

In a more politically charged environment, getting drugs across the finish line is increasingly complex and uncertain.

By Kelly Bilodeau • April 27, 2026

Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. 

By Gwendolyn Wu • April 22, 2026

Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push

The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as the future of genetic medicines.

By Michael Gibney • April 21, 2026

Can an LSD candidate do for anxiety what Spravato did for depression?

Definium Therapeutics is expecting late-stage data for two anxiety trials in the coming months, teeing up a potential approval.

By Meagan Parrish • April 17, 2026

Will cancer drugmakers ever conquer p53?

The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.

By Kelly Bilodeau • April 15, 2026

Biotech’s IPO comeback; Trump’s tariff loophole for pharma

Biotech IPOs gain long-lost momentum, and pharma companies find a way around the White House’s harsh tariffs.

By PharmaVoice Staff • April 10, 2026

Women have awaited a revolution in menopause. It hasn’t arrived.

Persistent barriers are still hindering drug development for a host of menopause symptoms.

By Kelly Bilodeau • April 8, 2026

Evommune bucked biotech IPO drought and is focused on the long game

Evommune went public late last year and is taking on stiff competition in immunology with a recent mid-stage clinical win.

By Michael Gibney • April 7, 2026

AI’s next trick? Revealing new disease targets for drug R&D

A wave of AI-driven platforms bucks the traditional approach of hunting for new molecules and instead focuses on pinpointing the underlying cause of disease.

By Meagan Parrish • April 3, 2026

Will Pfizer’s Lyme disease gamble pay off or set the space back?

As the disease spreads into new regions, the urgency for prevention is growing.

By Kelly Bilodeau • April 1, 2026

mRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cuts

Research into areas like cancer could become collateral damage of a broader anti-mRNA push, according to a new study.

By Alexandra Pecci • March 31, 2026

Big Pharma goes nuts over food allergies — again

Novartis’ acquisition of Excellergy for up to $2 billion portends a potential new wave of medicines for food allergies.

By Michael Gibney • March 31, 2026

Novo’s FDA voucher victory; biotech’s rigid glass ceiling

While Novo Nordisk collected a win through the FDA’s new voucher program, the initiative remains unpredictable and controversial.

By PharmaVoice Staff • March 27, 2026